An international randomized trial in Langerhans cell histiocytosis (LCH) has been initiated by the Histiocyte Society. This report reviews the rationale, design, and progress of LCH‐I, which compares etoposide (VP‐16) and vinblastine in the treatment of disseminated LCH. Data on the risk of etoposide‐associated (therapy‐induced) malignancy, in the setting of histiocytosis, are reviewed. The available evidence leads to the recommendation that the study of etoposide in LCH should be continued. © 1994 Wiley‐Liss, Inc.
- monocyte‐macrophage system
- secondary malignancies
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Cancer Research